Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.